Abstract
It is unclear whether the chemotherapy response improves after exposure to immunotherapy. Antiangiogenic agents have been shown to stimulate the immune system and cause synergistic effects that stimulate tumor shrinkage. We conducted a retrospective study to evaluate improvement of the efficacy of ramucirumab plus docetaxel after the failure of nivolumab as a PD-1 inhibitor. From February 2016 to December 2017, 152 patients with non-small cell lung cancer (NSCLC) administered nivolumab in our institution were identified. We reviewed the records of 20 NSCLC patients administered ramucirumab plus docetaxel after nivolumab failure. The overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) were investigated. Pegylated granulocyte colony-stimulating factor was prophylactically administered to 18 patients (90%) after the administration of ramucirumab plus docetaxel. The median age of the patients was 70 (range: 55-77) years. Twelve patients were male and eight were female. The histology was adenocarcinoma in 16 patients, squamous cell carcinoma in three, and other in one. The ORR of ramucirumab plus docetaxel was 60%, and the PFS and OS were 169 and 343 days, respectively. Among the 20 patients, 12 a...Continue Reading
References
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Julie R BrahmerSuzanne L Topalian
Feb 21, 2013·Cancer Immunology, Immunotherapy : CII·Rupal Ramakrishnan, Dmitry I Gabrilovich
Apr 23, 2013·Clinical and Experimental Immunology·S YasudaY Nakajima
Jun 17, 2014·Lancet·Edward B GaronMaurice Pérol
Nov 13, 2014·Journal of Translational Medicine·Anna R KwilasJames W Hodge
Nov 26, 2014·Journal of the National Cancer Institute·Ken Garber
May 6, 2015·Cancer Immunology Research·Leisha A Emens, Gary Middleton
May 16, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Amita PatnaikAnthony W Tolcher
Aug 28, 2016·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Kiyotaka YohKazuhiko Nakagawa
Oct 13, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Christian ManegoldEverett Vokes
Oct 18, 2016·The Lancet Oncology·Corey J LangerUNKNOWN KEYNOTE-021 investigators
Apr 14, 2017·Science Translational Medicine·Elizabeth AllenGabriele Bergers
Oct 25, 2017·Thoracic Cancer·Daiki OgawaraHiroshi Mukae
Nov 5, 2017·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Song Ee ParkJong-Mu Sun
Dec 2, 2017·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Gustavo SchvartsmanWilliam N William
Mar 24, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott GettingerJulie Brahmer
Apr 21, 2018·The Oncologist·Sakti ChakrabartiHarry H Yoon
Citations
Mar 13, 2019·Thoracic Cancer·Atsuto MouriHiroshi Kagamu
Aug 25, 2019·Cancer Chemotherapy and Pharmacology·Atsuto MouriHiroshi Kagamu
Jul 29, 2020·ESMO Open·Akinori SasakiKohei Shitara
Sep 20, 2019·Clinical Case Reports·Faisal ShahjehanPashtoon Murtaza Kasi
Mar 3, 2020·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Jingxing Yang, Chunfu Zhang
Apr 28, 2020·Respirology Case Reports·Komugi OkeyaHiroshi Tsuji
Jul 17, 2020·Therapeutic Advances in Medical Oncology·Robert J Walsh, Ross A Soo
Sep 5, 2020·Clinical Medicine Insights. Oncology·Wolfgang M BruecklEckart Laack
Aug 2, 2019·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·D IslaJ M Trigo
Sep 10, 2020·International Cancer Conference Journal·Hirofumi DoiKatsunari Miyamoto
Nov 27, 2020·Japanese Journal of Clinical Oncology·Akihito KawazoeMasanori Terashima
Dec 5, 2020·BMC Cancer·Wolfgang M BruecklGloria Zeitler
Feb 25, 2021·Thoracic Cancer·Hisao ImaiHiroshi Kagamu
Mar 13, 2021·Blood Advances·Reid W MerrymanAlex F Herrera
Jun 14, 2020·Bulletin du cancer·Clémence BasseDenis Moro-Sibilot
Jun 15, 2021·Frontiers in Oncology·Keiko TanimuraKoichi Takayama
Jul 22, 2021·Future Oncology·Martin MetzenmacherDaniel C Christoph
Aug 7, 2021·Journal of Cancer Research and Clinical Oncology·Fen WangShubin Wang
Nov 19, 2021·Thoracic Cancer·Masaki IshidaKoichi Takayama